<SEC-DOCUMENT>0001104659-25-039436.txt : 20250425
<SEC-HEADER>0001104659-25-039436.hdr.sgml : 20250425
<ACCEPTANCE-DATETIME>20250425161516
ACCESSION NUMBER:		0001104659-25-039436
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250425
DATE AS OF CHANGE:		20250425

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Carisma Therapeutics Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				262025616
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-87951
		FILM NUMBER:		25874223

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 401
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		2674916422

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 401
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sesen Bio, Inc.
		DATE OF NAME CHANGE:	20180516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AbbVie Biotechnology Ltd
		CENTRAL INDEX KEY:			0002014668
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THISTLE HOUSE, 4 BURNABY STREET
		CITY:			HAMILTON
		PROVINCE COUNTRY:   	D0
		ZIP:			HM11
		BUSINESS PHONE:		847-932-7900

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THISTLE HOUSE, 4 BURNABY STREET
		CITY:			HAMILTON
		PROVINCE COUNTRY:   	D0
		ZIP:			HM11
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001104659-24-033949</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: AbbVie Biotechnology Ltd -->
          <cik>0002014668</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, $0.001 par value</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>03/31/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001485003</issuerCik>
        <issuerName>Carisma Therapeutics Inc.</issuerName>
        <issuerCusip>14216R101</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>3675 Market Street, Suite 401</com:street1>
          <com:city>Philadelphia</com:city>
          <com:stateOrCountry>PA</com:stateOrCountry>
          <com:zipCode>19104</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(d)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>AbbVie Biotechnology Ltd.</reportingPersonName>
      <citizenshipOrOrganization>D0</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>1855871.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1855871.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1855871.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>4.4</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>The reported percentage is calculated based upon 41,788,096 shares of Common Stock outstanding as of March 26, 2025, as reported in the Issuer's annual report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 31, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Carisma Therapeutics Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>3675 Market Street, Suite 401, Philadelphia, PA, 19104</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>AbbVie Biotechnology Ltd.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>Thistle House, 4 Burnaby Street

Hamilton HM 11, Bermuda</principalBusinessOfficeOrResidenceAddress>
        <citizenship>See response to Item 4 on the cover page.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>See response to Item 9 on the cover page.</amountBeneficiallyOwned>
        <classPercent>See response to Item 11 on the cover page.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>See response to Item 5 on the cover page.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>See response to Item 6 on the cover page.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>See responses to Item 7 on the cover page.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>See response to Item 8 on the cover page.

The number of shares and percentages reflected herein include sales of common stock from March 31, 2025 through the date hereof.

The Board of Directors of AbbVie Biotechnology Ltd., which consists of Lindsey Bristow, Wayne Klintworth, Jonathan C. Clipper, Stephen Muldoon and Arthur Price and acts by majority vote, exercises voting and investment discretion of the reported securities. Each of Ms. Bristow and each of Messrs. Klintworth, Clipper, Muldoon and Price disclaim beneficial ownership of the reported securities and the filing of this statement shall not be deemed an admission of such beneficial ownership for purposes of Section 13.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>N</notApplicableFlag>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>Y</notApplicableFlag>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>AbbVie Biotechnology Ltd.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Arthur C. Price</signature>
        <title>Arthur C. Price/Director</title>
        <date>04/25/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
